Trial Profile
A study evaluating factors associated to persistence on Golimumab treatment in patients with Inflammatory Arthritis of the Biobadaser Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
- 04 Jun 2022 Results (n=125) assessing the probability of retention (persistence or drug survival) of golimumab in patients with rheumatic diseases when used after discontinuation of non-TNFi biologicals or tsDMARDs, presented at the 23rd Annual Congress of the European League Against Rheumatism
- 01 Oct 2021 Updated results assessing the probability of long-term retention of golimumab treatment during up to 7 years after treatment initiation in patients with rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA), published in the Clinical Rheumatology.